Pasithea (KTTA) director receives 152,783 stock options at $0.841

Rhea-AI Filing Summary

Pasithea Therapeutics Corp. director Alfred J. Novak received a grant of stock options covering 152,783 shares of common stock. The options have an exercise price of $0.8410 per share and were awarded under the company’s 2023 Stock Incentive Plan.

The options vest in full on the one-year anniversary of the grant date if Novak continues to serve as a director through that date. The award will also fully vest upon a Change in Control, as defined in the plan, providing additional equity-based compensation tied to his board service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Novak Alfred J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	152,783	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 152,783 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 152,783 shares Exercise price: $0.8410 per share Post-grant option holdings: 152,783 options +1 more

4 metrics

Option grant size 152,783 shares Stock Option (right to buy) granted to director Alfred J. Novak

Exercise price $0.8410 per share Conversion or exercise price of the granted stock option

Post-grant option holdings 152,783 options Total shares underlying options following this transaction

Option expiration 2036-04-30 Expiration date of the granted stock option

Key Terms

Stock Option (right to buy), 2023 Stock Incentive Plan, Change in Control

3 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

2023 Stock Incentive Plan financial

"award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan"

Change in Control financial

"shares underlying the Option will fully vest upon a Change in Control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Novak Alfred J

(Last) (First) (Middle)

1111 LINCOLN ROAD

SUITE 500

(Street)

MIAMI BEACH FLORIDA 33139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pasithea Therapeutics Corp. [ KTTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.841	05/01/2026		A		152,783		(1)	04/30/2036	Common Stock	152,783	$0	152,783	D

Explanation of Responses:

1. The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan).

	/s/ Alfred J. Novak	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Pasithea Therapeutics (KTTA) disclose about Alfred J. Novak’s Form 4 transaction?

Pasithea Therapeutics reported that director Alfred J. Novak received a stock option grant for 152,783 shares of common stock. The option was awarded under the 2023 Stock Incentive Plan and reflects equity-based compensation for his role as a director.

How many Pasithea Therapeutics (KTTA) options were granted to Alfred J. Novak?

Alfred J. Novak was granted stock options covering 152,783 shares of Pasithea Therapeutics common stock. This entire amount represents his holdings in this option award following the transaction, according to the reported total shares following the transaction field.

What is the exercise price of Alfred J. Novak’s Pasithea (KTTA) stock options?

The granted stock options have an exercise price of $0.8410 per share. This is the price at which Novak can purchase Pasithea Therapeutics common stock under the option, as specified in the Form 4 transaction details.

When do Alfred J. Novak’s Pasithea Therapeutics (KTTA) options vest?

The options will vest in full on the one-year anniversary of the grant date, provided Novak remains a director through that date. The filing also states the options fully vest upon a Change in Control, as defined in Pasithea’s 2023 Stock Incentive Plan.

Under which plan were Alfred J. Novak’s Pasithea (KTTA) options granted?

The option award was granted under Pasithea Therapeutics’ 2023 Stock Incentive Plan, as amended. This plan governs the terms of equity awards, including vesting conditions and the definition of a Change in Control that can accelerate vesting.

What happens to Alfred J. Novak’s Pasithea (KTTA) options if there is a Change in Control?

If a Change in Control, as defined in the 2023 Stock Incentive Plan, occurs, all shares underlying Novak’s option will fully vest. This accelerates vesting compared to the normal one-year schedule tied to continued board service.